

INSTRUCTIONS FOR USE FOR:





Edwards Lifesciences Corporation, et al. Exhibit 1126, Page 1 of 15

D

Α

)

RM

DOCKE.

A

RM

Α

TABLE OF CONTENTS

| DESCRIPTION | Page 1 | |
|--------------------------------|--------|--|
| INTENDED USE | Page 2 | |
| CONTRAINDICATIONS | Page 2 | |
| WARNINGS | Page 2 | |
| PRECAUTIONS | Page 2 | |
| ADVERSE EVENTS | Page 3 | |
| SUMMARY OF CLINICAL STUDIES | Page 4 | |
| INDIVIDUALIZATION OF TREATMENT | Page 9 | |
| HOW SUPPLIED | Page 9 | |
| STORAGE AND HANDLING | Page 9 | |
| RECOMMENDED MATERIALS | Page 9 | |
| DIRECTIONS FOR USE | Page 9 | |

Edwards Lifesciences Corporation, et al. Exhibit 1126, Page 2 of 15


INSTRUCTIONS FOR USE EXCLUDER BIFURCATED ENDOPROSTHESIS

Carefully read all instructions prior to use. Observe all warnings and precautions noted throughout these instructions. Failure to do so may result in complications.

DESCRIPTION

The EXCLUDER Bifurcated Endoprosthesis (EXCLUDER Endoprosthesis) is a device that provides endovascular treatment of infrarenal abdominal aortic aneurysms (AAA). The EXCLUDER Endoprosthesis is comprised of two components, the Trunk-Ipsilateral Leg Endoprosthesis (Trunk) (Figure 1) and the Contralateral Leg Endoprosthesis (Figure 2). The graft material is expanded polytetrafluoroethylene and fluorinated ethylene propylene (ePTFE and FEP), and is supported by nitinol wire along its external surface. Nitinol anchors and an ePTFE/FEP sealing cuff are located near the aortic end of the trunk. An ePTFE/FEP sleeve is used to constrain the endoprostheses on the leading end of the delivery catheters (Figures 3A, 3B, and 3C). Deployment of both endoprosthesis components initiates from the leading (aortic) end and proceeds toward the trailing (iliac) end of the delivery catheter. The ePTFE/FEP sleeve remains *in situ* between the endoprosthesis and the vessel wall.


Figure 1: Trunk-Ipsilateral Leg Endoprosthesis



Trunk-Ipsilateral Leg Endoprosthesis Radiopaque Markers

- Three (3) short markers at the aortic end.
- One (1) long and one (1) short marker at the endoprosthesis bifurcation level. The long
 marker denotes the contralateral leg side location and orientation.
- One (1) marker ring at the opening of the contralateral leg hole.
- One (1) short marker at the iliac end of the ipsilateral leg.


Figure 2: Contralateral Leg Endoprosthesis



Contralateral Leg Endoprosthesis Radiopaque Markers

• One (1) marker at each end

Figure 3A: EXCLUDER Endoprosthesis Delivery Catheter



Edwards Lifesciences Corporation, et al. Exhibit 1126, Page 3 of 15

Figure 3B: Constrained EXCLUDER Endoprosthesis (Trunk-Ipsilateral) on Delivery Catheter with Radiopaque Markers





Figure 3C: Constrained EXCLUDER Endoprosthesis (Contralateral) on Delivery Catheter with Radiopaque Markers



INTENDED USE

The EXCLUDER Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal AAA disease and who have appropriate anatomy.

CONTRAINDICATIONS

Known contraindications include, but are not limited to:

- Significant thrombus at the arterial implantation sites, specifically proximal aortic neck and distal
 iliac artery interface
- Severe proximal aortic neck angulation > 60°
- Infrarenal aortic neck < 15 mm in length
- Ilio-femoral access vessel morphology which is not compatible with vascular access techniques, devices and accessories.

WARNINGS

- Minimize handling of the constrained endoprosthesis during preparation and insertion to decrease the risk of endoprosthesis contamination and infection.
- Do not advance the device outside of the sheath.
- Do not rotate the Trunk or the Contralateral Leg delivery catheter while the endoprosthesis is inside the introducer sheath. Catheter breakage or premature deployment may occur.
- Do not rotate the Trunk delivery catheter beyond 360° to avoid delivery system damage and/or
 premature deployment.
- Do not rotate the Contralateral Leg delivery catheter during delivery. Catheter breakage or premature deployment may occur.
- Do not attempt to withdraw the undeployed endoprosthesis through the 18 Fr or 12 Fr introducer sheath valve. The sheath and catheter must be removed together.
- Do not attempt to reposition the endoprosthesis after deployment has been initiated. Vessel damage or device misplacement may result.
- Do not continue advancing any portion of the delivery system if resistance is felt during advancement of the guidewire, sheath, or catheter. Stop and assess the cause of resistance. Vessel or catheter damage may occur.
- Incorrect deployment or migration of the endoprosthesis may require surgical intervention.
- Do not cover significant renal or mesenteric arteries (exceptions are inferior mesenteric and iliofemoral) with the endoprosthesis. Vessel occlusion may occur.
- Do not use delivery catheter for high pressure fluid injections.

PRECAUTIONS

- Do not resterilize; for single use only.
- Do not use if damaged or if sterile barrier has been compromised.
- Do not use after the "use by" (expiration) date printed on the label.

Edwards Lifesciences Corporation, et al. Exhibit 1126, Page 4 of 15

DOCK

R

Μ

Δ

ADVERSE EVENTS

Adverse events that may require intervention include, but are not limited to: infection; bleeding at the site of catheter and sheath placement; lymph fistula; local neurologic damage; ilio-femoral vascular access anatomy complications including vascular trauma, occlusion, arteriovenous fistula, thrombosis and/or pseudoaneurysm; trauma to the aortic or ilio-femoral vessel wall, including dissection, perforation, rupture or erosion; fever and localized inflammation; microembolization and macroembolization; bowel ischemia; aortoenteric fistula; acute hepatic failure; renal failure or other renal complications; respiratory complications; congestive heart failure; arrhythmia; myocardial infarction; paraplegia; stroke; incomplete device component deployment; improper endoprosthesis component placement; endoprosthesis component migration; stent fracture; graft material failure or dilatation, erosion, puncture, separation of graft material from stent; endoprosthesis occlusion; endoprosthesis infection; endoleak; continued aneurysm enlargement; aneurysm rupture and death.

Edwards Lifesciences Corporation, et al. Exhibit 1126, Page 5 of 15

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.